Saturna Capital’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$65.8M Sell
1,790,627
-281,992
-14% -$13.4M 0.92% 29
2025
Q4
$105M Sell
2,072,619
-2,034
-0.1% -$104K 1.4% 21
2025
Q3
$115M Sell
2,074,653
-49,039
-2% -$2.87M 1.48% 22
2025
Q2
$147M Sell
2,123,692
-21,067
-1% -$1.43M 1.98% 17
2025
Q1
$149M Buy
2,144,759
+32,811
+2% +$2.71M 2.23% 16
2024
Q4
$182M Sell
2,111,948
-20,090
-0.9% -$2.17M 2.46% 12
2024
Q3
$254M Sell
2,132,038
-3,967
-0.2% -$529K 3.32% 7
2024
Q2
$305M Sell
2,136,005
-3,686
-0.2% -$488K 4.05% 6
2024
Q1
$275M Buy
2,139,691
+12,917
+0.6% +$1.54M 3.79% 6
2023
Q4
$220M Sell
2,126,774
-2,250
-0.1% -$223K 3.43% 6
2023
Q3
$194M Sell
2,129,024
-5,300
-0.2% -$467K 3.42% 4
2023
Q2
$173M Sell
2,134,324
-2,250
-0.1% -$184K 2.99% 6
2023
Q1
$170M Sell
2,136,574
-750
-0% -$53.2K 3.29% 6
2022
Q4
$145M Sell
2,137,324
-5,818
-0.3% -$341K 3.11% 6
2022
Q3
$107M Buy
2,143,142
+530
+0% +$28.4K 2.6% 8
2022
Q2
$119M Sell
2,142,612
-4,920
-0.2% -$273K 2.82% 8
2022
Q1
$119M Sell
2,147,532
-4,000
-0.2% -$205K 2.4% 12
2021
Q4
$120M Buy
2,151,532
+9,346
+0.4% +$506K 2.16% 14
2021
Q3
$110M Sell
2,142,186
-16,340
-0.8% -$790K 2.22% 13
2021
Q2
$90.4M Buy
2,158,526
+4,300
+0.2% +$167K 1.85% 14
2021
Q1
$72.6M Buy
2,154,226
+9,900
+0.5% +$353K 1.62% 20
2020
Q4
$74.9M Buy
2,144,326
+2,350
+0.1% +$81.2K 1.69% 20
2020
Q3
$74.4M Hold
2,141,976
1.89% 15
2020
Q2
$70.1M Hold
2,141,976
1.97% 15
2020
Q1
$68.5M Buy
2,141,976
+1,714
+0.1% +$51K 2.22% 12
2019
Q4
$61.9M Buy
2,140,262
+2,862
+0.1% +$79.2K 1.68% 20
2019
Q3
$55.3M Buy
2,137,400
+3,344
+0.2% +$84.6K 1.6% 23
2019
Q2
$54.5M Hold
2,134,056
1.6% 23
2019
Q1
$55.8M Sell
2,134,056
-1,172
-0.1% -$28.8K 1.63% 21
2018
Q4
$49.2M Buy
2,135,228
+900
+0% +$20K 1.66% 21
2018
Q3
$50.3M Sell
2,134,328
-2,600
-0.1% -$63.5K 1.47% 28
2018
Q2
$49.3M Hold
2,136,928
1.58% 23
2018
Q1
$52.6M Buy
2,136,928
+324
+0% +$8.51K 1.67% 22
2017
Q4
$57.3M Buy
2,136,604
+400
+0% +$10.2K 1.76% 19
2017
Q3
$51.4M Buy
2,136,204
+4,236
+0.2% +$95.7K 1.67% 21
2017
Q2
$45.7M Sell
2,131,968
-2,200
-0.1% -$44.4K 1.52% 25
2017
Q1
$36.6M Sell
2,134,168
-5,530
-0.3% -$96.3K 1.24% 40
2016
Q4
$38.4M Sell
2,139,698
-195,610
-8% -$3.55M 1.35% 36
2016
Q3
$48.6M Buy
2,335,308
+9,602
+0.4% +$238K 1.58% 18
2016
Q2
$62.5M Sell
2,325,706
-2,336
-0.1% -$64.1K 2% 11
2016
Q1
$64.9M Sell
2,328,042
-464
-0% -$12.4K 2.08% 9
2015
Q4
$67.6M Buy
2,328,506
+13,408
+0.6% +$371K 2.09% 9
2015
Q3
$62.8M Sell
2,315,098
-70,000
-3% -$1.98M 1.97% 11
2015
Q2
$65.3M Sell
2,385,098
-78,816
-3% -$2.22M 1.83% 12
2015
Q1
$65.8M Buy
2,463,914
+914
+0% +$21K 1.76% 12
2014
Q4
$52.1M Buy
2,463,000
+3,700
+0.2% +$82.6K 1.36% 22
2014
Q3
$58.6M Hold
2,459,300
1.57% 13
2014
Q2
$56.8M Hold
2,459,300
1.48% 16
2014
Q1
$56.1M Hold
2,459,300
1.48% 14
2013
Q4
$45.4M Hold
2,459,300
1.16% 27
2013
Q3
$41.6M Hold
2,459,300
1.11% 29
2013
Q2
$38.1M Buy
+2,459,300
New +$40.9M 1.04% 33

Other funds holding NVO

Saturna Capital's NVO Position: Q1 2026 in Review

Saturna Capital reduced its Novo Nordisk (NVO) stake by 14% in Q1 2026, selling an estimated $13.4M and leaving 1,790,627 shares worth $65.8M. The position accounts for 0.92% of the portfolio, ranked #29.

Saturna Capital first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $305M in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Saturna Capital held 1,790,627 shares of Novo Nordisk worth $65.8M as of Q1 2026.
  • Saturna Capital sold 281,992 Novo Nordisk shares in Q1 2026, an estimated $13.4M.
  • Novo Nordisk made up 0.92% of Saturna Capital's portfolio in Q1 2026, its #29 holding.
  • Saturna Capital first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
  • Saturna Capital's Novo Nordisk position peaked at $305M in Q2 2024.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Saturna Capital's 13F filing for Q1 2026, filed 12 May 2026.